Table 1.

Commonly used CXCR2 chemical antagonists

Name	Structure	Model	Therapeutic use or clinical trial	Reference
Danirixin	1-[4-chloro-2-hydroxy-3-[(3S)-piperidin-3-yl] sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea	Rat	Phase II for COPD	[41-43]
SCH527123 (MK-7123)	2-hydroxy-N,N-dimethyl-3-[[2-[[(1R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide	Mouse, rat	Phase II for COPD, asthma, traumatic brain injury, breast cancer, pancreatic cancer, acute-on-chronic liver failure	[44-46]
Reparixin	(2R)-2-[4-(2-methylpropyl)phenyl]-N-methylsulfonylpropanamide	Rat, mouse, and pig	Phase II for kidney and lung transplantation, metastatic breast cancer; Phase III for pancreatic islet transplantation in type 1 diabetes	[47-51]
AZD5069	N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide	Monkey	Phases Ib and II for head and neck cancer, metastatic castration-resistant prostate cancer; Phase II for asthma, COPD, bronchiectasis, coronary artery disease	[39■,52-55]
AZD8309	(R)-5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1-methylethyl)amino]-thiazolo[4,5-d]pyrimidin-2(3H)-one	Mouse	Phase I for rheumatoid arthritis, COPD, pancreatitis	[56,57]
G31P	6-Chloronicotinamide N-oxide 4a	Mouse, rat, and guinea pig	Aspiration pneumonia; ischemia and reperfusion injury; lung cancer; mastitis lesions; diabetic nephropathy; UAN kidneys; hepatocellular carcinoma; prostate cancer; ulcerative colitis	[58-61]
Ladarixin	(1,1-dioxo-1λ6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone	Mouse	Type 1 diabetes	[62]

COPD, chronic obstructive pulmonary disease; UAN, uric acid nephropathy.